Table 1.
Clinical characteristics and kidney outcomes among individuals with IgAN categorized by steroid responder score
| High SRS, n = 29 | Medium SRS, n = 33 | |||||
|---|---|---|---|---|---|---|
| No ISn = 10 | ISn = 19 | P-valuea | No ISn = 18 | ISn = 15 | P-valuea | |
| Clinical parameters | ||||||
| Age, years | 48.5 (33.8, 52.2) | 41.4 (34.3, 47.3) | 0.49 | 48.2 (35.9, 59.6) | 52.9 (38.4, 61.7) | 0.64 |
| Male, n (%) | 4 (40.0) | 5 (26.3) | 0.67 | 6 (33.7) | 7 (46.7) | 0.43 |
| Systolic BP, mmHg | 140 (118, 152) | 130 (120, 150) | 0.80 | 124 (110, 134) | 125 (116, 140) | 0.33 |
| Diastolic BP, mmHg | 75 (70, 84) | 72 (70, 80) | 0.50 | 70 (60, 81) | 75 (70, 80) | 0.44 |
| eGFR, mL/min/1.73 m2 | 63 (20, 83) | 51 (37, 81) | 0.76 | 59 (35, 78) | 55 (34, 101) | 0.73 |
| Proteinuria, g/g | 3.5 (1.7, 4.2) | 4.6 (2.7, 6.9) | 0.28 | 1.7 (1.0, 1.9) | 2.0 (1.4, 3.1) | 0.04 |
| RASB, n (%) | 10 (100) | 18 (94.7) | 1.00 | 18 (100) | 15 (100) | – |
| SNRS Low, n (%) High, n (%) | 7 (70.0) 3 (30.0) | 7 (36.8) 12 (63.2) | 0.13 | 11 (61.1) 7 (38.9) | 9 (60.0) 6 (40.0) | 0.95 |
| Global sclerosis, % | 32.5 (23.4, 53.5) | 25.0 (13.8, 38.4) | 0.11 | 25.0 (14.4, 37.3) | 33.3 (11.1, 46.1) | 0.42 |
| Kidney outcomes | ||||||
| Rapid progression | 3 (30.0) | 1 (5.3) | 0.10 | 1 (5.6) | 1 (6.7) | 1.00 |
| Kidney failure, n (%) | 3 (30.0) | 0 | 0.03 | 1 (5.6) | 0 | 1.00 |
| Follow up, months | 18.5 (9.4, 33.1) | 17.2 (6.7, 29.6) | 0.55 | 19.5 (9.9, 35.0) | 32.7 (21.6, 66.3) | 0.07 |
BP, blood pressure; IS, immunosuppressant; RASB, renin-angiotensin-aldosterone system blocker; SRS, steroid responder score; SNRS, steroid non-responder score. Rapid progression was defined as 50% reduction in estimated glomerular filtration rate or kidney failure at 12 months.
aComparison between IS and no IS groups by Pearson Chi-squared or Fisher's exact test as appropriate for categorical variables and Mann–Whitney U test for continuous variables.